Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023
Share
Sunmax Biotechnology Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 423.23 million compared to TWD 322.73 million a year ago. Revenue was TWD 417.44 million compared to TWD 321.95 million a year ago. Net income was TWD 144.52 million compared to TWD 139.01 million a year ago. Basic earnings per share from continuing operations was TWD 2.65 compared to TWD 2.55 a year ago. Diluted earnings per share from continuing operations was TWD 2.65 compared to TWD 2.55 a year ago.
For the six months, sales was TWD 816.63 million compared to TWD 647.5 million a year ago. Revenue was TWD 810.52 million compared to TWD 646.71 million a year ago. Net income was TWD 272.69 million compared to TWD 271.97 million a year ago. Basic earnings per share from continuing operations was TWD 5.01 compared to TWD 4.99 a year ago. Diluted earnings per share from continuing operations was TWD 5 compared to TWD 4.99 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.